Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer

Table 3 Single-factor Cox regression analysis

Variable	Z	HR (95%CI)	P value
Age
≤ 60		Reference
> 60	0.853	1.247 (0.751-2.069)	0.393
Sex
Male		Reference
Female	-0.350	0.882 (0.437-1.782)	0.727
BMI
18.5–24		Reference
< 18.5 or > 24	0.333	1.089 (0.659-1.799)	0.739
ASA
1+2		Reference
3	-0.192	0.941 (0.503-1.758)	0.848
RECIST 1.1
Ineffective		Reference
Effective	-3.803	0.379 (0.230-0.625)	< 0.001
TRG
Effective		Reference
Ineffective	3.329	2.278 (1.403-3.698)	0.001
Tumor location
Lower		Reference
Upper	-1.622	0.579 (0.300-1.120)	0.105
Middle	0.996	1.319 (0.765-2.277)	0.319
Differentiation
Poorly		Reference
Moderate	-0.752	0.819 (0.487-1.378)	0.452
Well	-2.555	0.365 (0.168-0.791)	0.011
cT stage
2		Reference
3	1.105	1.432 (0.757-2.707)	0.269
4	3.594	3.721 (1.817-7.618)	< 0.001
cN stage
Negative		Reference
Positive	2.097	1.786 (1.039-3.072)	0.036
cTNM
II		Reference
III	2.132	1.935 (1.055-3.550)	0.033
IV	4.508	3.724 (2.103-6.597)	< 0.001
Tumor diameter
≤ 2		Reference
2-5	2.178	2.503 (1.096-5.715)	0.029
≥ 5	3.061	3.619 (1.588-8.248)	0.002
Laurnen
Enteric		Reference
Mixed type	-0.276	0.906 (0.447-1.833)	0.783
Diffuse	1.506	1.705 (0.852-3.415)	0.132

BMI: Body mass index; RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor Regression Grade; HR: Hazard ratio.